Claritev Corporation appointed Ben Letham to its Board of Directors as a Class I director effective September 14, 2026, filling the vacancy created by the passing of John Prince. Letham joins the Risk Committee and brings expertise in artificial intelligence from his role as a research scientist at Meta. This appointment supports the company's strategy to deploy AI across its solutions for healthcare clients. Claritev is a technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system.

Claritev Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Revenues reached $257.5 million, a 6.6% increase from Q2 2025, while net loss narrowed to $59.2 million compared to $62.6 million in the prior year period. Adjusted EBITDA rose 1.1% to $155.8 million with a margin of 60.5%. The company updated its full-year 2026 revenue guidance upward to $1 billion–$1.02 billion and adjusted free cash flow guidance to $5 million–$15 million. Claritev operates in the healthcare technology, data, and insights industry.

Claritev Corporation announced on July 6, 2026, the death of John Prince, a member of the Board of Directors. Mr. Prince had served on the Board since June 2023 and was a member of the Audit Committee. Claritev Corporation is a company whose specific industry is not disclosed in the filing.

Claritev Corporation announced on June 17, 2026, that the Department of Justice Antitrust Division has closed its grand jury investigation into the company's health insurance-related activities and concluded that the company is not under criminal investigation. The company is also responding to a civil investigative demand received on May 19, 2026. Claritev Corporation operates in the healthcare ecosystem, providing data platforms and solutions to improve transparency and accessibility.